---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-005702"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2026-02-09T23:59:59+00:00"
generated_at: "2026-05-16T03:58:54.625981+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Anixa reports extended survival in ovarian cancer CAR-T trial; regulatory approval for 100x dose escalation

## Summary
- 12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.
- No dose-limiting toxicities; protocol amended to escalate from 1x10^7 to up to 1x10^9 cells/kg (100x increase).
- Next cohort includes lymphodepletion to potentially enhance CAR-T efficacy in solid tumors.
- Three patients remain alive at 15, 14, and 8 months post-treatment.

## SEC filing metadata
- accession: 0001493152-26-005702
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2026-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315226005702/0001493152-26-005702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315226005702/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-005702
- JSON: https://secwatch.observer/filing/0001493152-26-005702.json
- Plain text: https://secwatch.observer/filing/0001493152-26-005702.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.